Meeting
2019 ASCO Annual Meeting
Results of the VENUS study: Bevacizumab efficacy and safety in platinum-sensitive recurrent ovarian cancer (OC)—A real-life ambispective study.
Authors
Isabelle Laure Ray-Coquard
Centre Léon-Bérard, Lyon, France
Isabelle Laure Ray-Coquard , Jerome Alexandre , Francois Goldwasser , Jean-Philippe Spano , Dominique Berton-Rigaud , Aude-Marie Savoye , Michel Fabbro , Fernando Bazan , Elsa Kalbacher , Nadia Raban , Claire Giraud , Virginie Pottier , Frédéric Selle , Anne Patsouris , Claire Garnier-Tixidre , Anne Mercier Blas , Jocelyne Provencal , Fabien Brocard , Jessica Berdougo-Tritz , Vincent Launay-Vacher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5540)
DOI
10.1200/JCO.2019.37.15_suppl.5540
Abstract #
5540
Poster Bd #
363
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Safety and efficacy of mitoxantrone hydrochloride liposome in patients with platinum-refractory or platinum-resistant ovarian cancer: A prospective, multicenter, open-label, single-arm, phase Ib clinical trial.
First Author: Yu Huang
Poster
2015 ASCO Annual Meeting
Efficacy and safety comparison between belotecan and topotecan in patients with recurrent or refractory ovarian cancer: A multi-center, randomized, open-labelled, parallel-group phase IIb trial.
First Author: Hee Seung Kim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of trifluridine/tipiracil in combination with bevacizumab in older and younger patients with refractory metastatic colorectal cancer: A subgroup analysis of the phase 3 SUNLIGHT trial.
First Author: Julien Taieb
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.
First Author: Miao Wang